Evidence map›Paper›PMID 33639888›Full record

ArticleBMC cancer2021

Adverse reactions of targeted therapy in cancer patients: a retrospective study of hospital medical data in China.

Ruofei Du, Xin Wang, Lixia Ma, Leon M Larcher, Han Tang, Huiyue Zhou, Changying Chen, Tao Wang

Abstract readComparative Study
In one paragraph

Article in BMC cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. A questionnaire-based cross-sectional survey of cutaneous adverse events in cancer patients treated with molecular targeted therapy and immunotherapies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025
    Article
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ruofei Du *The College of Nursing and Health of Zhengzhou University, Zhengzhou, 450001, China.
Xin Wang *The College of Nursing and Health of Zhengzhou University, Zhengzhou, 450001, China.
Lixia MaSchool of Statistics, Henan University of Economics and Law, Zhengzhou, 450046, China.
Leon M LarcherCentre for Comparative Genomics, Murdoch University, Perth, WA, 6150, Australia.
Han TangThe College of Nursing and Health of Zhengzhou University, Zhengzhou, 450001, China.
Huiyue ZhouThe College of Nursing and Health of Zhengzhou University, Zhengzhou, 450001, China.
Changying ChenThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. changying@zzu.edu.cn.ORCID https://orcid.org/0000-0003-2151-7351
Tao WangThe College of Nursing and Health of Zhengzhou University, Zhengzhou, 450001, China. wangtaomary@zzu.edu.cn.

Funding

China Postdoctoral Science Foundation in 2018: 2018M630839The National Natural Science Foundation of China 81773175
6 · The paper itself

Abstract

backgroundThe adverse reactions (ADRs) of targeted therapy were closely associated with treatment response, clinical outcome, quality of life (QoL) of patients with cancer. However, few studies presented the correlation between ADRs of targeted therapy and treatment effects among cancer patients. This study was to explore the characteristics of ADRs with targeted therapy and the prognosis of cancer patients based on the clinical data.

methodsA retrospective secondary data analysis was conducted within an ADR data set including 2703 patients with targeted therapy from three Henan medical centers of China between January 2018 and December 2019. The significance was evaluated with chi-square test between groups with or without ADRs. Univariate and multivariate logistic regression with backward stepwise method were applied to assess the difference of pathological characteristics in patients with cancer. Using the univariate Cox regression method, the actuarial probability of overall survival was performed to compare the clinical outcomes between these two groups.

resultsA total of 485 patients were enrolled in this study. Of all patients, 61.0% (n = 296) occurred ADRs including skin damage, fatigue, mucosal damage, hypertension and gastrointestinal discomfort as the top 5 complications during the target therapy. And 62.1% of ADRs were mild to moderate, more than half of the ADRs occurred within one month, 68.6% ADRs lasted more than one month. Older patients (P = 0.022) and patients with lower education level (P = 0.036), more than 2 comorbidities (P = 0.021), longer medication time (P = 0.022), drug combination (P = 0.033) and intravenous administration (P = 0.019) were more likely to have ADRs. Those with ADRs were more likely to stop taking (P = 0.000), change (P = 0.000), adjust (P = 0.000), or not take the medicine on time (P = 0.000). The number of patients with recurrence (P = 0.000) and metastasis (P = 0.006) were statistically significant difference between ADRs and non-ADRs group. And the patients were significantly poor prognosis in ADRs groups compared with non-ADRs group.

conclusionThe high incidence of ADRs would affect the treatment and prognosis of patients with cancer. We should pay more attention to these ADRs and develop effective management strategies.

Indexed as

AdultAgedAged, 80 and overChinaDrug EruptionsDrug-Related Side Effects and Adverse ReactionsFatigueFemaleGastrointestinal DiseasesHospital RecordsHumansHypertensionIncidenceKaplan-Meier EstimateMaleMiddle AgedAdverse reactionsCancer patientsHospitalizationQuality of lifeTargeted therapy

Identifiers

PMID33639888
PMCPMC7916285

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.